ERBB2 and breast cancer: Using the ROC Plotter platform, it has been observed that in patients with BC, higher PUM1 expression was associated with a lower pathological complete response to anti-endocrine treatment (Figure 5a; p = 0.043, Mann–Whitney U test; AUC = 0.657), an unfavorable response to anti-HER2 treatment (Figure 5b; p = 0.0058, Mann–Whitney U test; AUC = 0.609), and a higher pathological complete response to chemotherapy (Figure 5c; p = 2.8 × 10−8, Mann–Whitney U test; AUC = 0.585).